Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pan-tumor × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 373 Brain Neoplasms 148 Glioma 143 Gliosarcoma 123 Astrocytoma 107 Central Nervous System Neoplasms 101 Oligodendroglioma 68 Melanoma 66 Neuroblastoma 39 Medulloblastoma 30 Neoplasms 28 Neoplasm Metastasis 26 Ependymoma 26 Recurrence 25 Sarcoma, Ewing 21 Sarcoma 20 Rhabdomyosarcoma 17 Diffuse Intrinsic Pontine Glioma 15 Lymphoma 14 Ovarian Neoplasms 13 Breast Neoplasms 13 Neuroendocrine Tumors 11 Choroid Plexus Neoplasms 11 Carcinoma, Non-Small-Cell Lung 11 Small Cell Lung Carcinoma 10 Lung Neoplasms 10 Osteosarcoma 9 Optic Nerve Glioma 9 Neuroectodermal Tumors, Primitive 9 Spinal Cord Neoplasms 8

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡